Pharma BD Deal Intelligence
Sanofi obtained an exclusive worldwide license to ADEL-Y01, a humanized monoclonal antibody selectively targeting tau acetylated at lysine-280 (acK280) for Alzheimer's disease, plus related backup compounds. ADEL received an $80M non-refundable upfront payment and is eligible for up to $960M in development and commercial milestones (total up to $1.04B), plus tiered royalties on net sales reaching up to double-digit percentages. ADEL-Y01 is in a global Phase 1a/1b first-in-human study (healthy volunteers plus participants with mild cognitive impairment or mild Alzheimer's disease) under a U.S. FDA IND. ADEL co-developed the asset with Oscotec under a 2020 joint R&D agreement.